TrialInvestigational new drugs2021

Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.

Zhi-Qiang Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.